Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 326 to 350 of 797

TitleReference numberPublishedLast updated
Ravulizumab for treating paroxysmal nocturnal haemoglobinuriaTA698
Ofatumumab for treating relapsing multiple sclerosisTA699
Crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older (terminated appraisal)TA701
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxabanTA697
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA692
Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemiaTA694
Carfilzomib with dexamethasone and lenalidomide for previously treated multiple myelomaTA695
Avelumab for treating metastatic Merkel cell carcinomaTA517
Acalabrutinib for treating chronic lymphocytic leukaemiaTA689
Avelumab for untreated metastatic Merkel cell carcinomaTA691
Anakinra for treating Still's diseaseTA685
Blinatumomab for previously treated Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)TA686
Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapyTA687
Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic diseaseTA684
Erenumab for preventing migraineTA682
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Lenalidomide maintenance treatment after an autologous stem cell transplant for newly diagnosed multiple myelomaTA680
Baricitinib for treating moderate to severe atopic dermatitisTA681
Filgotinib for treating moderate to severe rheumatoid arthritisTA676
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphomaTA677
Omalizumab for treating chronic rhinosinusitis with nasal polyps (terminated appraisal)TA678
Dapagliflozin for treating chronic heart failure with reduced ejection fractionTA679
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA673
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)TA674
Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal)TA675

Results per page

  1. 10
  2. 25
  3. 50
  4. All